Zacks Research Has Bullish Estimate for NKTR FY2024 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Analysts at Zacks Research upped their FY2024 EPS estimates for Nektar Therapeutics in a report issued on Monday, January 6th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per share of ($0.76) for the year, up from their prior estimate of ($0.80). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

A number of other research firms have also recently commented on NKTR. BTIG Research reissued a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 target price for the company. B. Riley initiated coverage on shares of Nektar Therapeutics in a research report on Wednesday. They set a “buy” rating and a $4.00 target price for the company. Finally, HC Wainwright initiated coverage on shares of Nektar Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $6.50 target price for the company. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.08.

Nektar Therapeutics Stock Performance

NASDAQ NKTR opened at $1.03 on Thursday. The firm’s 50 day moving average price is $1.09 and its 200-day moving average price is $1.21. Nektar Therapeutics has a 52-week low of $0.48 and a 52-week high of $1.93. The company has a market cap of $189.99 million, a PE ratio of -1.23 and a beta of 0.59.

Hedge Funds Weigh In On Nektar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in Nektar Therapeutics by 2,822.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 532,663 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Nektar Therapeutics by 66.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after acquiring an additional 1,634,046 shares during the last quarter. Samlyn Capital LLC acquired a new position in shares of Nektar Therapeutics in the 2nd quarter worth approximately $11,728,000. Millennium Management LLC lifted its holdings in shares of Nektar Therapeutics by 56.1% in the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock worth $5,778,000 after acquiring an additional 1,674,924 shares during the last quarter. Finally, Eventide Asset Management LLC lifted its holdings in shares of Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after acquiring an additional 1,870,904 shares during the last quarter. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Nektar Therapeutics

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the transaction, the insider now directly owns 326,904 shares in the company, valued at $307,289.76. The trade was a 13.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mark Andrew Wilson sold 33,402 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the transaction, the insider now owns 351,892 shares in the company, valued at $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 155,575 shares of company stock valued at $149,878 over the last 90 days. Corporate insiders own 3.71% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.